INTRODUCTION
============

Since the first successful description of extracorporeal membrane oxygenation (ECMO) in 1971 ([@b1-cln_67p1157]), this modality of respiratory support has been investigated in several trials. In 1979, the first randomized trial of ECMO in acute respiratory distress syndrome (ARDS) patients resulted in nonsignificant differences in mortality between the control and ECMO groups ([@b2-cln_67p1157]). In 1986, Gattinoni et al. described, with good outcomes, the use of ECMO to remove carbon dioxide from the blood, enabling the use of low-frequency mechanical ventilation, which was reported to have resulted in a lower incidence of ventilation-associated lung injury ([@b3-cln_67p1157]). In 1994, Morris et al. conducted a randomized trial to test the effectiveness of this strategy of carbon dioxide (CO~2~) removal associated with low-frequency ventilation compared with conventional treatment ([@b4-cln_67p1157]). The trial was stopped early due to futility. Mechanical ventilation with suboptimal settings and high airway pressures in the CO~2~ removal arm may have been associated with the negative final result. In 2009, the CESAR trial demonstrated a reduction in mortality and disability at six months among severe ARDS patients using a combined strategy of ECMO and protective mechanical ventilation compared with conventional protective mechanical ventilation ([@b5-cln_67p1157]).

The renewed interest in the use of ECMO was also fostered by the 2009 epidemic of severe pneumonia due to influenza-A H1N1([@b6-cln_67p1157])-([@b13-cln_67p1157]). Young patients with refractory hypoxemia were common among those affected by this disease, and respiratory rescue with ECMO was carried out with excellent outcomes in Australia ([@b14-cln_67p1157]), the United Kingdom ([@b15-cln_67p1157]), and Italy ([@b16-cln_67p1157]). These data suggest a survival benefit of using ECMO in addition to conventional support ([@b15-cln_67p1157]). In Brazil, many patients with influenza-A H1N1 required mechanical ventilation ([@b17-cln_67p1157]), and some of them developed severe hypoxemia, in whom the case mortality reached 11.6% ([@b11-cln_67p1157]). The absence of centers in Brazil that specialize in ECMO limited the availability of adequate support for those patients ([@b18-cln_67p1157]).

We implemented an ECMO service in two hospitals in São Paulo, Brazil. We followed a stepwise approach, which included theoretical training of ECMO, the use of wet lab practice with ECMO in animals in the research facility, and finally the use of ECMO in patients at the bedside. The aim of this manuscript is to describe the first year of our experience using ECMO support in patients with severe hypoxemic respiratory failure.

METHODS
=======

The ECMO group comprised nurses, respiratory therapists, and physicians. The care for ECMO-supported patients was delivered by one physician, one nurse, two nursing assistants, and one respiratory therapist, all of whom were also in charge of three additional critically-ill patients ([@b19-cln_67p1157]).

ECMO support was indicated based on individual judgment of the following objective criteria ([@b20-cln_67p1157]):

Major criteria (both required):

-   Acute or acute-on-chronic pulmonary disease

-   Possibility of disease reversion

Complementary criteria (at least one required):

-   P/F ratio≤50 with FiO~2~ = 1 for at least 1 hour, with or without rescue maneuvers

-   P/F ratio≤50 with FiO~2~≥0.8 for at least 3 hours, despite rescue maneuvers

-   Hypercapnia with pH≤7.2 using a respiratory rate of at least 35 breaths per minute, with a tidal volume of 4--6 mL/kg of ideal body weight and a plateau pressure≤30 cmH~2~O

-   Murray\'s score (lung injury score)\>3.0 with the patient presenting a clinical deterioration

ECMO support was not administered to patients with severe chronic illness without the possibility of improvement of their quality of life.

The canulation of patients was performed percutaneously at the bedside with the Seldinger technique using femoral and jugular canulae (Edwards Lifesciences, Irvine, CA, EUA). In the three patients who were transferred from other hospitals, we initiated the ECMO support before the patient was transported. We primed the ECMO circuit with 600 mL of normal saline solution at room temperature. A centrifugal magnetic pump with a polymethylpentene oxygenation membrane (Rotaflow/Jostra Quadrox - D, Maquet Cardiopulmonary AG, Hirrlingen, Germany) was used for all patients.

Initially, the blood flow was maintained at 500 mL per minute until the system was filled with blood. Blood flow and sweep (gas) flow were subsequently increased to 2000 mL per minute when using the venous-venous (VV) configuration. The blood flow and sweep flow were then elevated in a 1:1 ratio, with a peripheral oxygen saturation target of at least 90%. When using the veno-arterial (VA) configuration, the blood flow was gradually elevated to 5000 mL per minute, and the sweep flow was set at 5 L per minute. The ECMO support settings were adjusted based on the arterial blood gases (in the VV configuration) or on the arterial blood pressure, vasopressor requirement, and serum lactate levels (in the VA configuration).

No prophylactic antibiotics were administered. Anticoagulation with heparin was initiated at the team\'s discretion, beginning with 1000 IU per hour without bolus and adjusted to reach an activated partial thromboplastin time ratio of 1.5--2.5.

Mechanical ventilation was adjusted to a positive end-expiratory pressure (PEEP) of 10-15 cmH~2~O, an inspired fraction of oxygen (FiO~2~) of 0.3 or the least possible value, a driving pressure of less than 10 cmH~2~O, and, if necessary, a respiratory rate of 10 breaths per minute ([@b5-cln_67p1157]). The parameters checked daily included arterial blood gases, clots in the system visible through transillumination, pump campanula auscultation, and flowmeter lubrication to maintain a good signal quality. The ECMO blood flow was adjusted to maintain a PaO~2~ greater than 55 mmHg, and the sweep flow was adjusted to keep the pH≥7.3 (through the PaCO~2~ modulation). Typical sedatives and analgesics were used if necessary to reach a Richmond agitation sedation scale (RASS) score of zero with no pain. Body temperature was kept between 36 and 37 degrees Celsius with an external apparatus adapted to the ECMO system.

A test to evaluate whether a patient could be weaned from ECMO support was carried out daily. The mechanical ventilation settings remained constant in patients with pressure support ventilation; in patients under controlled ventilation, the tidal volume was raised to 6 mL/ideal body weight or was maintained at a level sufficient to keep the plateau pressure \<25 cmH~2~O and the driving pressure \<15 cmH~2~O. In both situations, the FiO~2~ was set to 0.6. In the VV configuration, the test consisted of stopping the sweep flow. In the VA configuration, the test consisted of reducing both the blood flow and sweep flow to 1,000 mL per minute, with an ECMO FiO~2~ of 0.21. The weaning test was interrupted if the patient presented a mean arterial blood pressure \<65 mmHg, peripheral oxygen saturation \<85%, or respiratory distress (respiratory rate\>35 breaths per minute, accessory muscle use, abdominal muscle contraction, diaphoresis, hypertension, or intense complaints of dyspnea). After 1 hour, the patient was considered able to have the ECMO support removed (positive weaning test) if he or she was hemodynamically stable without elevations in inotropics or vasopressors, without respiratory distress, with a PaO~2~≥55 mmHg and a pH≥7.30. The decanulation was performed at the bedside in the venous-venous configuration after the reversal of anticoagulation. In the veno-arterial configuration, the arterial canulae withdrawal was performed in the surgical room.

Data are presented as medians (minimum--maximum), which were obtained using the R -- free source statistical package (Vienna, Austria, 2009) ([@b21-cln_67p1157]).

RESULTS
=======

During a one-year period, ten patients with severe respiratory and/or cardiac dysfunction were supported with ECMO. The general characteristics of patients are shown in [Table 1](#t1-cln_67p1157){ref-type="table"}. The patients were young and had extremely severe disease, as demonstrated by their high expected mortality rate ([Table 1](#t1-cln_67p1157){ref-type="table"}). The most common etiology of the acute cardiopulmonary dysfunction was community-acquired pneumonia, and six of the ten patients were transferred from outside ICUs.

The patients\' support and clinical statuses prior to ECMO are shown in [Table 2](#t2-cln_67p1157){ref-type="table"}. They had low partial pressure of oxygen to inspired fraction of oxygen (P/F) ratios, as well as elevated PEEP and plateau pressures. At least one rescue therapy strategy for refractory hypoxemia had been performed on each patient prior to the initiation of ECMO. We used five sets of 20 French canulae (five long venous and five short arterial canulae) and five sets of 22 French canulae to administer ECMO.

Data regarding the monitoring and physiological variables associated with ECMO support are shown in [Tables 3](#t3-cln_67p1157){ref-type="table"} and [4](#t4-cln_67p1157){ref-type="table"}. ECMO support enabled a significant reduction in tidal volume and FiO~2~ during its use.

[Table 5](#t5-cln_67p1157){ref-type="table"} presents the patient complications identified during ECMO support. Pneumothorax, thrombocytopenia, and hypoxic hepatitis were common complications of the procedure, and there were no significant vascular complications in our patients.

Regarding the weaning tests, our patients were supported by ECMO for a total of 92 days, during which time 89 autonomy tests were performed; nine tests were performed in patients with the VA configuration, and 80 tests were performed in patients with the VV configuration. Ten tests were compatible with the removal of ECMO support; however, in two tests (both in the venous-venous configuration), at the discretion of the team, the patient was maintained on ECMO support for one additional day. Seven tests failed due to hypotension in patients using the veno-arterial configuration, and 73 tests failed due to a peripheral saturation\<85% associated with respiratory distress.

Seven patients were ventilated with pressure support during the positive weaning test, with a respiratory rate of 25 (20-42) breaths per minute, tidal volume of 310 (290-500) mL, and PEEP of 8 (5-15) cmH~2~O. Analysis of the arterial blood gases after one hour into the weaning test revealed a pH of 7.392 (7.320-7.474), PaO~2~ of 81 (56-197) mmHg, PaCO~2~ of 41 (37-55) mmHg and SBE of 0.7 (-4--5.2) mEq/L.

[Table 6](#t6-cln_67p1157){ref-type="table"} shows the clinical outcomes of the ten patients. The median time of ECMO support was five days. The majority of the patients were successfully weaned from ECMO, and four patients survived to 60 days after hospital discharge.

DISCUSSION
==========

In these severely injured patients with an expected survival of less than 13%, this study demonstrated a survival of 40% when using ECMO for respiratory and/or cardiovascular support. Another interesting aspect of this study was the enrollment of patients with acquired immunodeficiency syndrome (AIDS), who are not candidates for ECMO support in classical ECMO referral centers due to their high morbidity and mortality rates ([@b22-cln_67p1157]). Of note, the two AIDS patients included in our study died; one death was due to meningitis and the other was due to severe liver failure, and both occurred after the removal of ECMO support. One of these AIDS patients required 32 days of ECMO support and died 11 days after ECMO weaning. However, AIDS is a common condition among the patients in the Brazilian public health care services ([@b23-cln_67p1157]), and the use of ECMO support for those patients cannot be denied *a priori* until it is evaluated in a prospective trial.

The high SOFA and simplified acute physiological score (SAPS) 3 scores at the beginning of ECMO support in our patients suggest late enrollment and late initiation of ECMO support. This issue could be corrected by the early recognition of severe ARDS and the early activation of the ECMO team. To this end, promoting the awareness of the methodology and the existence of a referral center within the local medical community is likely an important step.

The VV configuration has lower oxygen-transfer efficacy compared with the VA configuration due to recirculation ([@b24-cln_67p1157]). Therefore, one can expect to have patients with persistent hypoxemia during the administration of VV ECMO support, as occurred in three of our patients. The presence of pneumothorax was diagnosed at the time of ECMO support weaning (data not published). We postulate that these pneumothoraxes were the result of barotrauma caused by the increase in transpulmonary pressure necessary to maintain alveolar ventilation.

Central nervous system injury during ECMO support is very common ([@b25-cln_67p1157]). Among the patients in our study, it is interesting to note that two experienced a seizure; one occurred during the system pause for lubrification of the blood flowmeter, and the other occurred due to meningitis. Three patients underwent brain death; one case was due to a trauma-related carotid dissection, one was due to meningitis and one was due to severe and prolonged hypoxemia (∼12 h) prior to ECMO administration. The former patientalso developed severe hypoxia-related rhabdomyolysis and hypoxic hepatitis, and he was the only patient who was determined to be brain dead while receiving ECMO support, which is a challenging diagnosis ([@b26-cln_67p1157]).

Sixty percent of our patients were transported from an ICU to our referral ICUs, and all of them had ECMO support initiated *in loco*. The transportation of ECMO-supported patients with good results and survival has been described previously ([@b27-cln_67p1157],[@b28-cln_67p1157]). Three out of six of our patients survived. It thus appears that the transportation of patients during ECMO support is feasible in our service.

Another important point to discuss is the ECMO team. All members were trained to perform the canulation at the bedside using the Seldinger technique, and the team was also the staff responsible for the care of the patients in the ICU. There was no particular staff member designated exclusively for the care of the ECMO-supported patients, which is a staff configuration that can potentially reduce the costs of ECMO support.

Our patients were allowed to awaken after the ECMO installation and transport. Their comfort was maintained despite their severe lung injuries. Some patients presented respiratory compliances as low as 6 mL/cmH~2~O; however, when the membrane sweep flow was sufficiently high, those patients were usually comfortable while alert and oriented.

Only one patient was anticoagulated during the entire ECMO support. The coexistence of bleeding or severe coagulopathy in the remaining patients resulted in the contraindication of anticoagulation ([@b22-cln_67p1157]). The new ECMO systems have a heparin-bound surface, which allows the ECMO support to proceed with minimal or no anticoagulation ([@b29-cln_67p1157]). In addition to the surface technology, the use of a high blood flow through the system is likely associated with the preservation of the ECMO circuits.

Renal replacement therapy is frequently applied through the ECMO circuit ([@b30-cln_67p1157]). Eighty percent of our patients required continuous venous-venous hemofiltration, which was applied through an individual catheter, a choice we made to minimize manipulations of the ECMO system.

When oxygenation was improving and there was low respiratory compliance, we sometimes decided to apply a strategy of permissive hypercapnia to wean patients from ECMO support early. In this situation, if the kidney is normal, the elimination of chloride with metabolic compensation is normally promptly conducted ([@b31-cln_67p1157]); however, during continuous hemofiltration therapy, we occasionally found it useful to reduce the chloride concentration in the replacement fluid.

The use of ECMO support in severely ill patients in Brazil is possible in the presence of a structured team. Efforts must be made to recognize the necessity of extracorporeal respiratory support at an early stage and to prompt activation of the ECMO team.
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###### 

Characteristics of patients supported by ECMO.

  General Characteristics                                                           (n = 10)
  --------------------------------------------------------------------------------- ---------------
      Age -- yr                                                                     31 (14--71)
      Gender -- M/F -- n (%)                                                        5 (50)/5 (50)
      Weight -- kg                                                                  59 (46--84)
      Pre-ECMO LOS -- days [\*](#tfn2-cln_67p1157){ref-type="table-fn"})            9 (1--40)
      SAPS 3 score ^\#^                                                             94 (84--118)
      Expected mortality -- (%)                                                     95 (87--99)
      Duration of pre-ECMO hypoxemia (h)                                            9 (2--20)
  **Etiologic diagnosis**                                                           
      Community-acquired pneumonia                                                  5 (50)
      *P*. *jiroveci* pneumonia+AIDS [§](#tfn4-cln_67p1157){ref-type="table-fn"})   2 (20)
      Alveolar hemorrhage+SLE ^¶^                                                   1 (10)
      Traumatic pulmonary contusion                                                 1 (10)
      Nosocomial pneumonia                                                          1 (10)
  **Comorbidities**                                                                 
      Hypertension                                                                  2 (20)
      Diabetes                                                                      1 (10)
      Heart failure                                                                 1 (10)
      Atrial fibrillation                                                           1 (10)
  **Transfer**                                                                      
      No transfer                                                                   4 (40)
      By in-hospital transportation                                                 3 (30)
      By ambulance                                                                  2 (20)
      By helicopter                                                                 1 (10)

Quantitative data are shown as medians (minimum, maximum).

ECMO denotes extracorporeal membrane oxygenation LOS denotes length of stay.

\# SAPS denotes simplified acute physiological score.

AIDS denotes acquired immunodeficiency syndrome.

¶ SLE denotes systemic lupus erythematosus.

###### 

Pre-ECMO clinical status and support [§](#tfn7-cln_67p1157){ref-type="table-fn"}).

  Arterial blood gases                                                                    (n = 10)
  --------------------------------------------------------------------------------------- -----------------------------
      PaO~2~ -- mmHg                                                                      50 (36-56)
      PaCO~2~ -- mmHg                                                                     57 (31--142)
      P/F ratio                                                                           50 (36-56)
  **Mechanical ventilation**                                                              
      PEEP -- cmH~2~O                                                                     15 (10--23)
      FiO~2~                                                                              1 (1--1)
      Respiratory rate -- breaths/minute                                                  28 (18--90)
      Tidal volume -- mL                                                                  275 (130--400)
      Plateau pressure -- cmH~2~O                                                         31 (25--46)
  **Pre-ECMO respiratory rescue maneuvers**                                               
      Alveolar recruitment -- n (%)                                                       7 (70)
      Neuromuscular blockade -- n (%)                                                     6 (60)
      Corticosteroids -- n (%)                                                            4 (40)
      High frequency ventilation -- n (%) [\*](#tfn8-cln_67p1157){ref-type="table-fn"})   3 (30)
      Tracheal gas insufflation -- n (%)                                                  1 (10)
  **Hemodynamics**                                                                        
      Norepinephrine -- n (%)/dosage (mcg/kg/minute)                                      10 (100)/0.64 (0.28-- 5.12)
      Epinephrine -- n (%)/dosage (mcg/kg/minute)                                         2 (20)/0.44 (0.19--0.70)
      Dobutamine -- n (%)/dosage (mcg/kg/minute)                                          3 (30)/15 (4-20)
      Vasopressin -- n (%)/dosage (mcg/minute)                                            1 (10)/0.03
      Mean arterial blood pressure -- mmHg                                                63 (30--94)
      Heart rate -- beats/minute                                                          145 (109-180)
  **Metabolic**                                                                           
      Temperature - °C                                                                    37.4 (36.6--41.2)
      Lactate -- mEq/L                                                                    2.8 (1.6--4.1)
      pH                                                                                  7.17 (6.9--7.41)
      SBE -- mEq/L ^\#^                                                                   -2.3 (-21.9--5.6)
                                                                                          
  **Sedation, analgesia and  neuromuscular blockers**                                     
      SAS                                                                                 1.5 (1.0--3.0)
      Midazolam - n (%)/dosage (mg/kg/hour)                                               4 (40)/0.16 (0.11--0.42)
      Propofol - n (%)/dosage (mg/kg/hour)                                                4 (40)/0.73 (0.21--1.69)
      Fentanyl - n (%)/dosage (mcg/kg/hour)                                               7 (70)/2.25 (0.85--6.28)
      Thionembutal - n (%)/dosage (mg/kg/hour)                                            1 (10)/3
      Atracurium - n (%)/dosage (mg)                                                      5 (50)/50 (50--50)
      Cisatracurium - n (%)/dosage (mg)                                                   1 (10)/20

All quantitative data are presented as medians (minimum, maximum).

ECMO denotes extracorporeal membrane oxygenation.

High-frequency ventilation denotes high-frequency positive pressure ventilation (HFPPV).

\# SBE denotes standard base excess.

###### 

Respiratory and hemodynamic support and monitoring during extracorporeal membrane oxygenation.

  Clinical characteristics                                                                First day                    Throughout support           Last day
  --------------------------------------------------------------------------------------- ---------------------------- ---------------------------- --------------------------
      Lung injury score                                                                   3.00 (2.25--4.00)            3.00 (1.00--4.00)            2.00 (1.00--4.00)
      Sequential organ failure assessment (SOFA)                                          18 (16--19)                  14 (4--19)                   14 (4--18)
  **ECMO support ^¥^**                                                                                                                              
      ECMO configuration -- VV/VA -- n (%) ^£^                                            VV - 8 (80)/VA - 2 (20)      VV - 8 (80)/VA - 2 (20)      VV - 8 (80)/VA--2 (20)
      Blood flow -- mL/min                                                                4500 (2300--6400)            4500 (600--7000)             4000 (1000--6000)
      Sweep flow -- L/min                                                                 5.5 (3.0--10.0)              3.0 (0.2--10.0)              2.0 (0.2--8.0)
      Pump rotations - RPM                                                                3885 (2400--4855)            4000 (1500--5560)            3000 (1500--5560)
      FiO~2~                                                                              1.00 (0.40--1.00)            1.00 (0.40--1.00)            1.00 (0.40--1.00)
  **Ventilatory support**                                                                                                                           
      Patients on mechanical ventilation -- n (%)                                         10 (100)                     10 (100)                     9 (90)
      Pressure control ventilatory mode -- n (%)                                          5 (50)                       2 (20)                       2 (20)
      Pressure support ventilatory mode -- n (%)                                          3 (30)                       9 (90)                       7 (70)
      Bilevel ventilatory mode -- n (%)                                                   1 (10)                       1 (10)                       0 (0)
      Volume control ventilatory mode -- n (%)                                            1 (10)                       1 (10)                       0 (0)
      PEEP -- cmH~2~O                                                                     12 (10--18)                  13 (6--20)                   10 (6--15)
      FiO~2~                                                                              0.30 (0.30--0.60)            0.30 (0.21--0.80)            0.30 (0.21--0.60)
      Respiratory rate -- breaths/min                                                     18 (10--32)                  23 (9--65)                   20 (10--44)
      Expiratory tidal volume - mL                                                        150 (50--380)                185 (50--600)                260 (92--610)
      PaO~2~ -- mmHg                                                                      68 (49--126)                 66 (43--126)                 70 (50--126)
      PaCO~2~ - mmHg                                                                      39 (21--51)                  47 (21--77)                  43 (23--64)
  **Respiratory rescue maneuvers**                                                                                                                  
      Nitric oxide -- n (%)                                                               2 (20)                       2 (20)                       1 (10)
      Alveolar recruitment -- n (%)                                                       2 (20)                       2 (20)                       0 (0)
                                                                                                                                                    
  **Hemodynamic support**                                                                                                                           
      Dobutamine -- n (%)/mcg/kg/min [\*](#tfn10-cln_67p1157){ref-type="table-fn"})       6 (60)/15.0 (3.4--20.0)      5 (50)/10.0 (3.4--20)        3 (30)/20 (10--20)
      Epinephrine -- n (%)/mcg/kg/min [\*](#tfn10-cln_67p1157){ref-type="table-fn"})      4 (40)/0.28 (0.14--0.77)     4 (40)/0.23 (0.04--0.77)     2 (20)/0.06 (0.04--0.08)
      Norepinephrine -- n (%)/mcg/kg/min [\*](#tfn10-cln_67p1157){ref-type="table-fn"})   10 (100)/0.65 (0.04--2.82)   10 (100)/0.17 (0.02--2.82)   4 (40)/0.06 (0.04--1.75)
      Vasopressin -- n (%)/mcg/min [\*](#tfn10-cln_67p1157){ref-type="table-fn"})         2 (20)/0.04 (0.03--0.04)     4 (40)/0.03 (0.01--0.03)     2 (20)/0.04 (0.03--0.04)
      Nitroprusside -- n (%)/mcg/min [\*](#tfn10-cln_67p1157){ref-type="table-fn"})       0 (0)                        0 (0)                        1 (0)/0.5
      Mean arterial blood pressure -- mmHg                                                71 (30--120)                 88 (30--126)                 75 (60--126)

This is the maximum dosage administered during the analyzed period when on drug use.

\# This is the median dosage during the analyzed period when on drug use.

£ VV and VA denote the venous-venous and veno-arterial ECMO configuration, respectively.

¥ ECMO denotes extracorporeal membrane oxygenation.

###### 

Hematological, metabolic, infection and sedation support and monitoring of patients during extracorporeal membrane oxygenation.

  Hematological support                                                 First day                                                                Throughout support                                           Last day
  --------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------
      Hemoglobin -- g/dL                                                7.6 (4.7--11.5)                                                          7.5 (4.7--11.5)                                              7.0 (6.0--8.5)
      Platelet count -- platelets/mm^3^                                 120000 (41000--400000)                                                   84000 (7000--40000)                                          67000 (19000--254000)
      Patients on heparin therapy -- n (%)                              5 (50)                                                                   6 (60)                                                       3 (30)
      Heparin dosage -- (IU/h)                                          1000 (500--1000)                                                         1000 (500--1200)                                             1000 (500--1000)
      APTT ratio ^¶^                                                    1.7 (0.8--3.0)                                                           1.3 (0.8--3.3)                                               2.1 (1.9--2.1)
      International normalized ratio                                    1.5 (1.3--4.0)                                                           1.3 (1.1--4.4)                                               1.4 (1.1--3.0)
      Lactate dehydrogenase                                             1882 (1111--16173)                                                       2281 (491--31413)                                            2175 (1322--31143)
      Indirect bilirubin -- mg/dL                                       0.23 (0.01--2.27)                                                        0.29 (0.01--3.10)                                            0.38 (0.10--1.38)
      Packed red cell transfusion -- n (%)/units/patient                1 (10)/2                                                                 4 (40)/4 (3--11)                                             1 (10)/2
      Plasma transfusion -- n (%)/units/patient                         0 (0)/0                                                                  3 (30)                                                       1 (10)
      Platelet transfusion -- n (%)/units/patient                       0 (0)/0                                                                  6 (60)                                                       1 (10)
  **Metabolic support**                                                                                                                                                                                       
      Enteral energy intake -- kCal                                     0 (0--475)                                                               825 (0--1200)                                                638 (0--1200)
      Enteral protein intake - g                                        0 (0--19)                                                                36 (0--48)                                                   26 (0--48)
      Temperature - °C                                                  36.4 (35.0--41.2)                                                        36.4 (33.1--41.2)                                            36.2 (34.2--37.9)
      pH                                                                7.38 (7.11--7.51)                                                        7.39 (7.11--7.51)                                            7.37 (7.29--7.47)
      SBE -- mEq/L [§](#tfn20-cln_67p1157){ref-type="table-fn"})        -5.0 (-18.9--8.4)                                                        4.4 (-18.9--17)                                              1.6 (-13.3--11.1)
      Serum lactate -- mEq/L                                            4.4 (1.1--17.3)                                                          3.1 (0.8--19.7)                                              2 (1.2--17.0)
      Renal replacement therapy administration -- n (%)                 7 (70)                                                                   8 (80)                                                       7 (70)
      Renal replacement therapy mode -- n (%)                           CVVHD 1(10)/CVVHF 6 (60) [®](#tfn17-cln_67p1157){ref-type="table-fn"})   CVVHF 8 (80) [®](#tfn17-cln_67p1157){ref-type="table-fn"})   CVVHF 7 (70) [®](#tfn17-cln_67p1157){ref-type="table-fn"})
      Adenosine citrate dextrose (ACD-A 2.2%) administration -- n (%)   2 (20)                                                                   5 (50)                                                       5 (50)
      Fluid balance -- mL                                               1203 (-1028--7564)                                                       428 (-4997--8612)                                            200 (-1355--3037)
  **Infection support**                                                                                                                                                                                       
      Patients using antibiotics -- n (%)                               9 (90)                                                                   10 (100)                                                     9 (90)
      C-reactive protein -- mg/dL                                       177 (43--465)                                                            165 (8--465)                                                 167 (40--336)
      Leukocytes -- leuckocytes/mm^3^                                   13620 (2510--60350)                                                      13620 (2510--60350)                                          11995 (7000--41980)
  **Sedation**                                                                                                                                                                                                
      SAS ^€^                                                           2 (1--5)                                                                 4 (1--6)                                                     3 (1--4)
      Patients receiving sedatives/analgesics -- n (%)                  9 (90)                                                                   9 (90)                                                       5 (50)
      Fentanyl -- n (%)/mcg/kg/h ^\#^                                   8 (80)/1.1 (0.4--6.3)                                                    8 (80)/1.0 (0.3--6.3)                                        5 (50)/0.8 (0.3--2.3)
      Propofol -- n (%)/mg/kg/h ^\#^                                    3 (30)/0.8 (0.5--2.1)                                                    3 (30)/0.9 (0.2--2.1)                                        0 (0)
      Midazolam -- n (%)/mg/kg/h ^\#^                                   1 (10)/0.08                                                              1 (10)/0.10                                                  0 (0)
      Dexmedetomidine -- n (%)/mcg/kg/h ^\#^                            1 (10)/0.5                                                               2 (20)/0.2 (0.2--0.5)                                        0 (0)

This is the maximum dosage used during the analyzed period.

£ VV and VA denote the venous-venous and veno-arterial ECMO configuration, respectively.

\# This is the median dosage during the analyzed period.

CVVHF denotes continuous venous-venous hemofiltration, and CVVHD denotes continuous venous-venous hemodialysis.

¥ ECMO denotes extracorporeal membrane oxygenation.

¶ APTT denotes activated partial thromboplastin time.

SBE denotes standard base excess.

€ SAS denotes sedation agitation score.

###### 

Complications during ECMO support [\*](#tfn22-cln_67p1157){ref-type="table-fn"}).

  Respiratory                                                                        
  ---------------------------------------------------------------------------------- --------
      Pneumothorax -- n (%) ^\#^                                                     3 (30)
      Persistent hypoxemia -- n (%) [§](#tfn24-cln_67p1157){ref-type="table-fn"})    3 (30)
  **Gastrointestinal**                                                               
      Hypoxic hepatitis -- n (%) ^¶^                                                 5 (50)
      Digestive hemorrhage -- n (%)                                                  2 (20)
  **Hematological**                                                                  
      Hemolysis [®](#tfn26-cln_67p1157){ref-type="table-fn"})                        3 (30)
      Thrombocytopenia (\<150000) -- n (%)                                           9 (90)
      Thrombocytopenia (\<100000) -- n (%)                                           8 (80)
      Thrombocytopenia (\<50000) -- n (%)                                            7 (70)
  **ECMO system**                                                                    
      Minor canulae bleeding -- n (%)[©](#tfn27-cln_67p1157){ref-type="table-fn"})   2 (20)
      Flowmeter loss of signal -- n (%)                                              2 (20)
      Blood leakage -- n (%)                                                         0 (0)
      Re-circulation -- n (%) ^¥^                                                    1 (10)
      Centrifugal pump cavitation -- n (%) ^£^                                       1 (10)
      Shaking circuit -- n (%) ^£^                                                   1 (10)
      Sudden reduction in blood flow -- n (%) ^£^                                    3 (20)
  **Central nervous system**                                                         
      Seizure -- n (%)                                                               2 (20)
      Brain death -- n (%)                                                           1 (10)

ECMO denotes extracorporeal membrane oxygenation.

\# The pneumothoraxes occurred at the end of ECMO support in all patients.

Persistent hypoxemia was defined as a PaO~2~≤50 mmHg despite an ECMO blood flow \>5500 L/minute, a PEEP≥10 cmH~2~O and a FiO~2~≥0.6.

¶ Hypoxic hepatitis was diagnosed when alanine transaminase and aspartate aminotransferase were acutely elevated by at least five-fold soon after the initiation of ECMO support.

Hemolysis was considered in patients who had brown urine, brown effluent fluid from renal replacement therapy and/or a haptoglobin level\<36 mg/dL (low limit of normality in our laboratory).

Sufficient bleeding to require a cannula insertion dressing change more than twice a day.

¥ Re-circulation was considered when persistent hypoxemia occurred with ECMO system drainage and an oxygen blood saturation of\<70%.

£ Centrifugal pump cavitation, a shaking circuit and a sudden decrease in blood flow constitute the "suck-up" phenomena, which are secondary to the pre-pump lower pressure associated with drainage cannula misplacement or hypovolemia.

###### 

Outcomes of patients treated with ECMO support.

  General outcomes                                                                       
  -------------------------------------------------------------------------------------- ------------
      ICU LOS -- days [\*](#tfn30-cln_67p1157){ref-type="table-fn"})                     18 (3--50)
      Hospital LOS -- days                                                               31(3--97)
      Time on ECMO support -- days ^\#^                                                  5 (3--32)
      Weaning from ECMO support -- n (%) [§](#tfn32-cln_67p1157){ref-type="table-fn"})   8 (80)
      ICU discharge -- n (%)                                                             4 (40)
      Hospital discharge -- n (%) ^¶^                                                    4 (40)
      Survival to 60 days -- n (%)                                                       4 (40)
  **Causes of death**                                                                    
      Brain death -- n (%)[©](#tfn34-cln_67p1157){ref-type="table-fn"})                  3 (30)
      Multiple organ failure -- n (%)                                                    2 (20)
      Liver failure -- n (%)                                                             1 (10)

ICU denotes the intensive care unit, and LOS denotes the length of stay.

\# ECMO denotes extracorporeal membrane oxygenation.

n (%) denotes the number and percentage of patients weaned from ECMO support.

¶ All patients were discharged free from dialysis and oxygen support.

One patient died during ECMO support; two patients died after the ECMO weaning, one due to *Escherichia coli* meningitis and one due to a hemispheric stroke resulting from a traumatic internal carotid dissection.

[^1]: Park M, Azevedo LC, Carvalho CR, Schettino GP and Costa EL were responsible for the data collection, patients support and manuscript drafting. Mendes PV, Amato MB, Tucci M, Maciel AT, Taniguchi LU, Barbosa EV, Nardi RO, Ignacio MN, Machtans CC, Neves WA and Hirota AS were responsible for data collection and patients support.
